Outcomes in COVID-19 edaravone studies

All studies   Mortality   Ventilation   ICU   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -50% 1 38 Improvement, Studies, Patients Relative Risk Mortality -50% 1 38 Ventilation 75% 1 38 ICU admission -10% 1 38 RCTs -50% 1 38 Late -50% 1 38 Edaravone for COVID-19 c19early.org November 2025 Favorsedaravone Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Moslemi (RCT) -50% 1.50 [0.28-7.99] death 3/19 2/19 ICU patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Late treatment -50% 1.50 [0.28-7.99] 3/19 2/19 50% higher risk All studies -50% 1.50 [0.28-7.99] 3/19 2/19 50% higher risk 1 edaravone COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Effect extraction pre-specified(most serious outcome) Favors edaravone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Moslemi (RCT) -50% 1.50 [0.28-7.99] 3/19 2/19 ICU patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Late treatment -50% 1.50 [0.28-7.99] 3/19 2/19 50% higher risk All studies -50% 1.50 [0.28-7.99] 3/19 2/19 50% higher risk 1 edaravone COVID-19 mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Favors edaravone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Moslemi (RCT) 75% 0.25 [0.06-1.03] 2/19 8/19 ICU patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.054 Late treatment 75% 0.25 [0.06-1.03] 2/19 8/19 75% lower risk All studies 75% 0.25 [0.06-1.03] 2/19 8/19 75% lower risk 1 edaravone COVID-19 mechanical ventilation result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.054 Favors edaravone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Moslemi (RCT) -10% 1.10 [0.21-5.72] 19 (n) 19 (n) ICU patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.92 Late treatment -10% 1.10 [0.21-5.72] 19 (n) 19 (n) 10% higher risk All studies -10% 1.10 [0.21-5.72] 19 (n) 19 (n) 10% higher risk 1 edaravone COVID-19 ICU result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.92 Favors edaravone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Moslemi (RCT) -50% 1.50 [0.28-7.99] death 3/19 2/19 ICU patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Late treatment -50% 1.50 [0.28-7.99] 3/19 2/19 50% higher risk All studies -50% 1.50 [0.28-7.99] 3/19 2/19 50% higher risk 1 edaravone COVID-19 serious outcome c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Effect extraction pre-specified(most serious outcome) Favors edaravone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Moslemi (RCT) -50% 1.50 [0.28-7.99] death 3/19 2/19 ICU patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Late treatment -50% 1.50 [0.28-7.99] 3/19 2/19 50% higher risk All studies -50% 1.50 [0.28-7.99] 3/19 2/19 50% higher risk 1 edaravone COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Effect extraction pre-specified(most serious outcome) Favors edaravone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Moslemi (RCT) -50% 1.50 [0.28-7.99] 3/19 2/19 ICU patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Late treatment -50% 1.50 [0.28-7.99] 3/19 2/19 50% higher risk All studies -50% 1.50 [0.28-7.99] 3/19 2/19 50% higher risk 1 edaravone COVID-19 RCT mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Favors edaravone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Moslemi (RCT) -50% 1.50 [0.28-7.99] death 3/19 2/19 ICU patients Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Late treatment -50% 1.50 [0.28-7.99] 3/19 2/19 50% higher risk All studies -50% 1.50 [0.28-7.99] 3/19 2/19 50% higher risk 1 edaravone COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Effect extraction pre-specified(most serious outcome) Favors edaravone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Moslemi (RCT) -50% 1.50 [0.28-7.99] death 3/19 2/19 ICU patients Improvement, RR [CI] Treatment Control Moslemi (RCT) 75% 0.25 [0.06-1.03] ventilation 2/19 8/19 ICU patients Moslemi (RCT) -10% 1.10 [0.21-5.72] ICU 19 (n) 19 (n) ICU patients Edaravone COVID-19 outcomes c19early.org November 2025 Favors edaravone Favors control